In today’s scientific era, molecular research has paved the way
for the development of pharmaceuticals that are improving the lives of millions
of patients. The discovery of the human immunodeficiency retrovirus as the
causative agent of AIDS led to the development of reverse transcriptase inhibitors
such as zidovudine. Monoclonal antibodies directed against tumor necrosis
factor α have changed the lives of many patients with rheumatoid arthritis.
Imatinib mesylate, a specific inhibitor of the bcr-abl protein kinase, has
transformed the prognosis for patients with chronic myeloid leukemia; and
as drug-resistant variants arise, DNA sequencing can identify the mutations
responsible and provide a rational basis for further drug development.1- 2 In 2004 the first angiogenesis inhibitors
were approved by the US Food and Drug Administration, in one case for treatment
of metastatic colorectal cancer and in another for age-related macular degeneration.3- 4 There is reason for optimism that this
is just the beginning, and that the huge investments in molecular biology
and genomics research made 10 to 30 years ago will provide an increasingly
robust flow of new and effective medicines.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
A, Source: Office of Extramural Research, National Institutes of Health.
B, Fields included are anatomy; biochemistry; biology; biomedical engineering;
biophysics; cell and molecular biology; genetics, microbiology, immunology,
and virology; nutrition; pathology; pharmacology; physiology; zoology and
other biosciences. Source: Survey of Graduate Students and Postdoctorates
in Science and Engineering via WebCASPAR, National Science Foundation. C,
Source: Survey of Graduate Students and Postdoctorates in Science and Engineering
via WebCASPAR, National Science Foundation. B, C reproduced with permission.12
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Thank you for submitting a comment on this article. It will be reviewed by JAMA editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 13
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.